This article first appeared in the Global Cause on the Infectious Diseases campaign. A printed publication was enclosed within every copy of New Scientist magazine and the content is available online on the Global Cause website. The campaign featured exclusive content from key thought leaders and industry voices about pharmaceutical industry collaboration in developing COVID-19 treatments and vaccines
As countries grapple with how best to tackle COVID-19, Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), was invited to speak at the Chatham House Weekly COVID- 19 Pandemic Briefing to explain how the biopharmaceutical industry is collaborating on an unprecedented scale to accelerate the development and manufacturing of COVID-19 treatments and vaccines.
“I think industry has really stepped up. They are an integral part of the Access to COVID-19 Tools (ACT) Accelerator, they are very engaged in the vaccine development,” said Jeremy Farrar of the Wellcome Trust, in a Chatham House Weekly COVID- 19 Pandemic Briefing. He called to “use the best of what only industry can bring in terms of the know how to develop new products.”
This was the perfect set up for me, at the following briefing, where I joined Emma Ross, Senior Consulting Fellow of the Global Health Programme of Chatham House, to answer questions on how the pharmaceutical industry is collaborating on an unprecedented scale to develop COVID-19 technologies and tools, the challenges and concerns the industry faces and the best approaches to adopt to ensure equitable and affordable access to COVID-19 therapeutics and vaccines for all; leaving no one behind.
Read the full article here